23 Jul, 2026
According to Straits Research the global blood culture tests market size was valued at $6.67 billion in 2025 and is projected to grow from $7.36 billion in 2026 to $16.14 billion by 2034, at a CAGR of 10.32% during the forecast period 2026–2034.
The presence of microorganisms in the blood, such as bacteria, yeast, and other types of microorganisms, can be determined by performing a blood culture on the patient. Blood cultures are diagnostic techniques used to find infections in the blood and pinpoint their source. This study does not examine the services that come with the products; its sole focus is on the products themselves.
In addition, the government's implementation of stringent regulations for the development and manufacturing of blood culture tests product is a driving force behind the market expansion. These regulations ensure that only the highest quality products are produced. The rising awareness of the importance of preventative healthcare in the fight against infectious diseases is another factor contributing to the market expansion.
An alarming rise in blood and bloodstream infections is driving the global market for blood culture tests. Infectious diseases cause the most death and illness worldwide. Blood culture tests can diagnose and treat these diseases quickly, preventing them from becoming life-threatening. Laboratory technicians and researchers used blood culture media, assays, kits and reagents, software and services, and other consumables to detect microorganisms and control infection. Blood culture tests can identify the infection-causing agent. This allows for an accurate treatment prognosis and helps prevent disease-related side effects. Diagnostic device R&D and government regulations have increased. Rising investment in R&D by healthcare sectors to develop new consumables, instruments, and software drives the global market. R&D investments support the development of new products and services and the company's long-term growth.
The rise in older adults worldwide is the primary factor driving expansion in the market for blood culture tests worldwide. This is because older adults have a significantly increased risk of developing immunosenescence, a condition in which the immune system does not function correctly and reduces immune system activity. As a direct consequence, older adults have a higher risk of contracting an infection. In addition, the incidence of sepsis is noticeably higher in the population of people aged 65 and older.
Diagnosing bloodstream infections in the laboratory provides a high level of accuracy and accurate responses, both intertwined with the ideas that underlie emerging technologies. Recent technological developments include single-plex or multiplex polymerase chain reaction assays, examples of technologies that fall under molecular-based technology. These tests help differentiate between various organisms, such as Staphylococcus aureus, and other types of organisms that are not Staphylococcus aureus. In addition, new assays that are known as blood culture identification assays (BCID) have been developed recently. These assays are aimed at a total of 27 different targets, including Gram-negative targets, multiple Gram-positive targets, and additional Candida targets. The sample testing results can be obtained with these assays in less than an hour, and they can be used to detect Klebsiella pneumonia carbapenemase (KPC).
North America is anticipated to dominate the global blood culture tests market and is expected to reach USD 3.94 billion in 2030, growing at a CAGR of 8.3% during the forecast period. The presence of the target market, rising interest in the healthcare industry, and rising disposable income in the area are all anticipated to contribute to the market's expansion. The availability of highly developed healthcare infrastructure and cutting-edge diagnostic products in countries like the United Kingdom, France, and Switzerland contribute to an increase in the demand for blood culture tests to achieve a timely diagnosis. In addition, during the forecast period, the prevalence of bloodstream infections in Europe is anticipated to increase the demand for blood culture tests.
sales@straitsresearch.com